Onkológia 2/2023

Dual EGFR mutation in patient with non-small cell lung cancer

Propose: Targeted therapy has markedly changed the outcomes of patients with non-small cell lung cancer (NSCLC). Molecular genetic analysis is a key to individually tailored treatment. Tyrosine kinase inhibitors (TKIs) are the current standard treatment in advanced NSCLC with mutations in gene for epidermal growth factor receptor. Case: In the case report, we present a rarely occurring dual EGFR mutation in 80-year-old patient with non-small cell lung cancer. Conclusion: Presented case of patient with dual EGFR mutation opens a question about impact of multiple EGFR mutations in patients with NSCLC treated with tyrosine kinase inhibitors in context of therapeutic individualization given the complexity and heterogeneity of underlying resistances.

Keywords: non-small cell lung cancer, EGFR mutation, T790M, TKI, osimertinib